Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Kantarjian

Showing results (1-10 of 283) with videos related to

Pageof 29
Sort By:
Hematology/Oncology Clinics of North America|January 9, 2001
Adult acute lymphocytic leukemia. Introduction and questions related to current programsH M Kantarjian
The American Journal of Medicine|August 1, 1994
Adult acute lymphocytic leukemia: critical review of current knowledgeH M Kantarjian
Hematology/Oncology Clinics of North America|March 20, 2001
Adult acute lymphocytic leukemia. Future research directionsH M Kantarjian
Seminars in Oncology|December 12, 2001
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemiasH M Kantarjian, M Talpaz
Annals of the New York Academy of Sciences|February 24, 2001
Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignanciesM Beran, H M Kantarjian
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1994
Management of adult acute lymphocytic leukemia: present issues and key challengesA Preti, H M Kantarjian
Blood|October 9, 1998
Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemiaH M Kantarjian, M Talpaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1988
Definition of the accelerated phase of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Blood|May 15, 1995
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trialH M Kantarjian, M Talpaz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Moving toward individualized target-based therapies in acute myeloid leukemiaA Bazinet, H M Kantarjian
Pageof 29

Showing results (1-10 of 283) with videos related to

Sort By:
Pageof 29
Hematology/Oncology Clinics of North America|January 9, 2001
Adult acute lymphocytic leukemia. Introduction and questions related to current programsH M Kantarjian
The American Journal of Medicine|August 1, 1994
Adult acute lymphocytic leukemia: critical review of current knowledgeH M Kantarjian
Hematology/Oncology Clinics of North America|March 20, 2001
Adult acute lymphocytic leukemia. Future research directionsH M Kantarjian
Seminars in Oncology|December 12, 2001
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemiasH M Kantarjian, M Talpaz
Annals of the New York Academy of Sciences|February 24, 2001
Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignanciesM Beran, H M Kantarjian
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1994
Management of adult acute lymphocytic leukemia: present issues and key challengesA Preti, H M Kantarjian
Blood|October 9, 1998
Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemiaH M Kantarjian, M Talpaz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1988
Definition of the accelerated phase of chronic myelogenous leukemiaH M Kantarjian, M Talpaz
Blood|May 15, 1995
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trialH M Kantarjian, M Talpaz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 24, 2022
Moving toward individualized target-based therapies in acute myeloid leukemiaA Bazinet, H M Kantarjian
Pageof 29